Kyverna Therapeutics (KYTX) Interest Expenses (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Interest Expenses data on file, last reported at $35.1 million in Q1 2026.

• Quarterly Interest Expenses rose 3547.25% year-over-year to $35.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.1 million (up 668.56% YoY) and the FY2025 annual result came in at $43.8 million, up 1326.0% from the prior year.
• Interest Expenses rose to $35.1 million in Q1 2026, from $355000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $35.1 million in Q1 2026 to a low of $47000.0 in Q4 2023.
• A 4-year average of $6.4 million and a median of $1.8 million in 2024 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2024 — Interest Expenses surged 6193.62% — and 2025, when it plunged 88.0%.
• Tracing KYTX's Interest Expenses over 4 years: stood at $47000.0 in 2023, then surged by 6193.62% to $3.0 million in 2024, then sank by 88.0% to $355000.0 in 2025, then jumped by 9793.8% to $35.1 million in 2026.
• The last three Interest Expenses figures came in at $35.1 million (Q1 2026), $355000.0 (Q4 2025), and $16.1 million (Q3 2025), per Business Quant data.